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Head and neck neoplasms
Oral cavity
A B S T R A C T
Objectives: Tumour-positive resection margins are a major problem during oral cancer surgery. gGlu-HMRG is a
tracer that becomes ﬂuorescent upon activation by gamma-glutamyltranspeptidase (GGT). This study aims to
investigate the combination of gGlu-HMRG and a clinical ﬂuorescence imaging system for the detection of
tumour-positive resection margins.
Materials and methods: The preclinical Maestro and clinical Artemis imaging systems were compared in vitro and
ex vivo with cultured human head and neck cancer cells (OSC19, GGT-positive; and FaDu, GGT negative) and
tumour-bearing nude mice. Subsequently, frozen sections of normal and oral cancer tissues were ex vivo sprayed
with gGlu-HMRG to determine the sensitivity and speciﬁcity. Finally, resection margins of patients with sus-
pected oral cancer were ex vivo sprayed with gGlu-HMRG to detect tumour-positive resection margins.
Results: Both systems could be used to detect gGlu-HMRG activation in vitro and ex vivo in GGT positive cancer
cells. Sensitivity and speciﬁcity of gGlu-HMRG and the Artemis on frozen tissue samples was 80% and 87%,
respectively. Seven patients undergoing surgery for suspected oral cancer were included. In three patients
ﬂuorescence was observed at the resection margin. Those margins were either tumour-positive or within 1mm of
tumour. The margins of the other patients were clear (≥8mm).
Conclusion: This study demonstrates the feasibility to detect tumour-positive resection margins with gGlu-HMRG
and a clinical ﬂuorescence imaging system. Applying this technique would enable intraoperative screening of the
entire resection margin and allow direct re-resection in case of tumour-positivity.
Introduction
Surgery remains the treatment of choice for the curative therapy of
squamous cell carcinoma (SCC), including oral cancer. A resection re-
quires wide margins to ensure no residual tumour tissue is left behind
after surgery. However, such resections often cause functional loss. In
the case of oral cancer, inadequate resection margins (i.e. close and
positive margins) are reported in up to 85% of these patients [1,2].
These patients more often develop local recurrences and regional neck
metastases, resulting in decreased survival rates [3]. Patients with oral
cancer often have leucoplakia, which makes intraoperative dis-
crimination between benign and malignant tissue challenging. In-
traoperative frozen section analysis is sometimes used in oral cancer
surgery to assess whether the resection margin is free of tumour.
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However, this method has certain drawbacks. Sampling errors can re-
sult in incorrect diagnosis. A pathologist is required for histopatholo-
gical examination where the subsequent processing of the biopsy would
then delay the surgical procedure [4,5]. Ideally, the entire resection
surface should be evaluated during the operation, but this is not pos-
sible with current strategies.
Recently, several clinical studies with tumour-targeted ﬂuorescent
tracers demonstrated the feasibility to visualize tumours, and more
importantly their margins, during surgery [6–8]. Cetuximab was con-
jugated to the near-infrared ﬂuorescent dye IRDye800CW. The combi-
nation enabled demarcation of tumours with millimetre-resolution in
oral cancer patients [9]. These results are promising, but these tracers
have several disadvantages. First, intravenous administration may lead
to adverse reactions. Cetuximab, for example, can cause severe infusion
reactions and other harmful side eﬀects [10]. Second, antibody-based
tracers have long plasma half-lives, and intravenous administration
requires relatively high doses to have suﬃcient tracers reach the tu-
mour. Unbound tracers in the systemic circulation result in non-speciﬁc
background ﬂuorescence. This reduces the signal-to-background ratio
(SBR) and potentially hampers visualization of speciﬁc ﬂuorescence.
Third, administration of labelled antibodies to patients needs to be
applied several days before surgery, which requires an additional visit
or earlier admission to the hospital. This requires additional planning
and is inconvenient for patients. Fourth, clinical translation of novel
ﬂuorescent tracers is costly, time-consuming and requires speciﬁc ex-
pertise.[11]
All these issues can be solved by topically applying activatable
ﬂuorescent tracers instead. This strategy requires a much lower dose
and does not suﬀer from nonspeciﬁc ﬂuorescence from unbound tra-
cers. Moreover, spraying activatable tracers on only resected tissue only
would not require costly translational research. Furthermore, such an
approach would completely diminishes the risk of adverse events.
Recently, γ-glutamyl hydroxymethyl rhodamine green (gGlu-
HMRG) was developed for the detection and diagnosis of preclinical
cancer [12]. HMRG remains quenched until cleaved in the presence of
the enzyme gamma-glutamyltranspeptidase (GGT). After activation
HMRG emits ﬂuorescence with a peak at 525 nm. Application of gGlu-
HMRG on resected material was investigated to identify tumour-posi-
tive resection margins in breast cancer patients [13]. Mizushima et al.
[14] showed that ﬂuorescence imaging with gGlu-HMRG could be
Fig. 1. Flow cytometry of the GGT-positive cell line OSC19 (A) and the negative cell line FaDu (B). The majority of the activation of gGlu-HMRG on OSC19 cells occurs within the ﬁrst ten
minutes (C). HMRG is internalized after activation (D; 40 times enlarged).
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useful for screening of early-stage head and neck SCC. Shimane et al.
demonstrated that gGlu-HMRG has high sensitivity for ex vivo detec-
tion of oral SCC [15]. However, to have clinical signiﬁcance for oral
cancer patients during surgery, intraoperative detection of microscopic
tumour-positive margins of SCC is required.
The feasibility of this technique was demonstrated with a preclinical
ﬂuorescence imaging system [12], which cannot be used in the oper-
ating room. To investigate if an intraoperative clinical imaging system
such as the Artemis [16] can be used to image the activation of gGlu-
HMRG, we compared the sensitivity with the Maestro preclinical
Fig. 2. The Maestro was capable of generating high
signal-to-background ratios (SBR) in OSC19 cells,
especially with 50 µM and 100 µM (A). The Artemis
demonstrated already an increase of SBRs at lower
concentrations (C). FaDu showed very weak ﬂuores-
cence originating from activated gGlu-HMRG with both
ﬂuorescence systems (B & D).
Fig. 3. Shown are examples of in vivo and ex vivo
measurements with the Maestro and colour and
ﬂuorescence images made ex vivo with the Artemis.
On the right matching signal-to-background ratios of
a control (n=1) and tongues sprayed with gGlu-
HMRG (n=4). Both systems could be used to re-
cognize GGT positive cancer cells of in in vitro and in
vivo studies.
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imaging system. The aims of this study are outlined as follows: (A) to
compare those aforementioned combinations using human head and
neck cancer cell lines, (B) to determine the sensitivity and speciﬁcity of
gGlu-HMRG on ex vivo frozen human oral cancer tissues, and (C) to
study the feasibility to detect microscopic tumour-positive resection
margins in oral cancer patients.
Materials and methods
Flow cytometry and ﬂuorescence microscopy
The protocol adopted for this study was described previously by
Urano et al. [12]. Flow cytometry was performed with the BD LSR-II
Flow Cytometer for cell evaluation and subsequent cell measurements
were analysed with FlowJo software (FlowJo, LLC, Ashland, OR, USA).
Two human SCC cell lines, OSC19 (oral cancer; GGT overexpressing)
and FaDu (hypopharyngeal cancer; GGT low expressing), were used.
After incubation with gGlu-HMRG, the cells were nuclear stained with
Hoechst ﬂuorescent stain (Invitrogen). Images were obtained every
5min for 1 h after application using the Leica microsystems LAS
AF6000 modular systems at 20× magniﬁcation. Quantiﬁcation of the
signal over time was assessed using the in-house developed software
program, called ‘Stacks’, which operates using the Microsoft Windows
operating system. Each measurement was corrected to make translation
between separate images possible after which a mask was created based
on the last image (t= ’60). Within the mask the average intensity was
measured for all images and the standard deviation was calculated as a
percentage of the intensity.
Imaging systems
Two imaging systems were compared. The preclinical CRi Maestro
imaging system (CRi Inc., Woburn, MA, Perkin Elmer, Waltham, MA,
USA) consists of a 300W xenon-based excitation light source with seven
possible excitation and emission ﬁlter pairs, covering the complete
spectral range from 500 to 950 nm. Every pixel can be analysed by a
process called spectral unmixing, in which the signals from the back-
ground and ﬂuorophore are separated. The software quantiﬁes each
pixel and determines relative concentration of the ﬂuorophore present
in that pixel [17,18].
The Artemis ﬂuorescence imaging system [16] (Quest Medical
Imaging B.V., The Netherlands) used in this study consisted of a “white”
light source, and a light source at 490 nm. Colour video and ﬂuores-
cence images are simultaneously acquired on separate sensors and
displayed in real-time. A pseudo-coloured (lime green) merged image of
the colour video and ﬂuorescence images is also displayed. The in-
tensities of the light sources and exposure times could be controlled
with the Artemis software.
In vitro imaging of gGlu-HMRG
OSC19 or FaDu cells (2× 104 cells/well) were seeded into a 12-well
plate. The cells were incubated at a timepoint of 48 h after seeding, with
gGlu-HMRG at ﬁve diﬀerent concentrations (1, 2, 10, 50, and 100 μM)
in PBS for 30min. PBS without cells, but with similar concentrations of
gGlu-HMRG was used as the background signal to calculate a SBR.
Images were obtained using the Maestro and Artemis camera system,
and analysed by measuring ROIs with the Maestro and ImageJ software
(v.1.48, National Institutes of Health, USA), respectively.
Table 1
Scoring results.
Normal Fluorescence Malignant Fluorescence
Neg Weak Pos Neg Weak Pos
GGT Neg 6 5 2 GGT Neg 0 0 0
Weak 2 0 0 Weak 0 2 3
Pos 0 0 0 Pos 1 0 9
Fig. 4. Example of ﬂuorescence microscopy of normal and malignant frozen tissue (2.5 times enlarged). Ten minutes after spraying with gGlu-HMRG, the normal tissue displayed weak
ﬂuorescence. Malignant tissue became clearly ﬂuorescent, which correlated with positive GGT staining.
Table 2




No. Diagnosis Margin RM ES
1 Keratinizing squamous
cell carcinoma
Clear (8mm) − + +
2 Parakeratosis,
hyperplasia
NA − − −
3 Keratinizing squamous
cell carcinoma
Tumour-positive + + +
4 Keratinizing squamous
cell carcinoma
Tumour-positive + ++ +
5 Keratinizing squamous
cell carcinoma
Clear (8mm) − + +
6 Squamous cell
carcinoma








RM: resection margin; ES: epithelial side; NA: not applicable; CIS: carcinoma in situ.
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In vivo imaging of gGlu-HMRG
The local animal welfare committee of Leiden University Medical
Center approved the animal experiments. OSC19 cancer cells (60.000
cells/10 μl medium) were injected into the submucosa of the tip of the
tongue of six to eight weeks-old female nude Balb/c mice (Charles River
laboratories, France). Health and tumour growth was monitored by
weighing and inspecting the mice at least twice a week. Tongue in-
spections were carried out under isoﬂurane gas anaesthesia.
One to two weeks after cell injection, when the tumour diameter
had reached approximately 5mm, gGlu-HRMG (100 µl, 50 µM in PBS)
was sprayed on the tongue under general anaesthesia (n= 4). A control
tongue (n=1) was sprayed with PBS. The tongues were imaged by the
Maestro imaging system 30min after topical application. Mice were
sacriﬁced and tongues were directly harvested for ex vivo imaging both
by Maestro and Artemis. SBRs were calculated with ImageJ.
To conﬁrm signal and tumour overlay, the tongues were cut into
cryosections of 10 µm after which they were stained by haematoxylin
and eosin (H&E).
Ex vivo evaluation of patient-derived cancer frozen specimen
Frozen tissues of 15 patients with oral cancer were analysed to
assess sensitivity and speciﬁcity. Normal tissue of the oral cavity of each
patient was used as a negative control. Tissues were obtained from the
Erasmus Medical Center (Rotterdam, The Netherlands) tissue bank.
Cryosections were cut into slices of 10 µm. The cryosections were im-
aged by ﬂuorescence microscopy (Leica microsystems DM5500 B,
Eindhoven, The Netherlands) at 0, 1, 5 and 10min after application of
gGlu-HMRG (50 µl of 50 µM in PBS). Fluorescence intensity (negative,
weak, or positive) was scored independently by two authors (MS &
HH). Subsequently, each slice was stained using an anti-GGT1 antibody
(dilution 1:800; ab55138, Abcam, Cambridge, UK). The staining of
epithelium was also scored (negative, weak, or positive) by two authors
(LH & HH). Concordance between ﬂuorescence and GGT status was
subsequently evaluated.
Ex vivo evaluation of resection margins after oral cancer surgery
Patients with suspected or biopsy-proven oral cancer and scheduled
to undergo resection with curative intent were eligible for inclusion.
Patients were excluded if they received: (A) radiotherapy, (B) had un-
dergone previous surgery in the oral cavity, or (C) diagnosed with
multiple primary oral tumours or any active autoimmune diseases (e.g.
Sjögren or lichen planus). The latter category was excluded for their
diﬀuse abnormalities in the oral cavity.
Fig. 5. Example of resection margin assessment with gGlu-HMRG and the clinical Artemis imaging system (upper two panels). Ten minutes after spraying on the tissue, several spots
became ﬂuorescent in the resection margin (arrows). In one patient with squamous cell carcinoma, focal expansion of a carcinoma in situ<1mm from the resection margin was
diagnosed with ﬂuorescence imaging (dashed arrow). The epithelial side was used as a positive control.
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The local medical ethical committee decided no formal approval
from patients was required, because the spray was applied ex vivo, the
tissue was handled anonymously, the outcomes did not inﬂuence
treatment, and the surgeon and pathologist were blinded for the study.
This pilot study was designed to prevent any potentially harmful
change in standard care.
Directly after surgery the edges (margins) of the primary specimen
were sprayed with 1ml of 50 µM gGlu-HRMG per 6 cm2. No in-
traoperative frozen sections were analyzed with these patients, only the
primary tumor resection specimen. Upcoming ﬂuorescent spots were
marked with ink. Subsequently, the epithelial side was sprayed, which
functioned as a positive control. Fluorescence imaging was performed
with the Artemis only. The resection margins were assessed for tumour
positivity after embedding into paraﬃn using standard of care. The
tissue was cut into slices of 10 µm and stained for H&E staining and
GGT (dilution 1:1600). Spots marked with ink were checked for tumour
and GGT status.
Results
Activation and uptake of gGlu-HMRG
Both the oral cancer cell line OSC19 and the hypopharyngeal cancer
cell line FaDu, were evaluated for tracer uptake by ﬂow cytometry.
OSC19 was found to provide activation of gGlu-HMRG, while the FaDu
cell line was identiﬁed as almost negative in responding to GGT
(Fig. 1A and B). More than 70% of the total intracellular activation of
gGlu-HMRG already occurred within 1min (Fig. 1C), but the signal
continued to increase up to 60min (Fig. 1D). The relatively high stan-
dard deviations are explained by the translation between the images at
diﬀerent times and the movement of cells. Activation and internaliza-
tion of gGlu-HMRG by OSC19 cells was clearly visible with ﬂuorescence
microscopy (Fig. 1D).
Maestro vs. Artemis
Tracer activation by OSC19 and FaDu cells was imaged by com-
paring the performance of the Maestro, allowing spectral unmixing, and
the clinical Artemis imaging system. The Maestro, which facilitates
spectral unmixing, was capable of generating higher SBRs in OSC19
cells, whilst the Artemis showed already an increase of SBRs at lower
concentrations (Fig. 2A and C). The highest SBRs were achieved at an
applied concentration of 100 µM performed on the Maestro instrument.
However, even when a concentration of 50 µM was applied, the dif-
ference in detection between the two systems did not prove to be sta-
tically signiﬁcant (p= .15). The latter concentration was therefore
considered optimal and used for further experiments. Moreover, 50 µM
resulted in the highest SBR with the Artemis. FaDu showed very weak
ﬂuorescence originating from activated gGlu-HMRG with both ﬂuor-
escence systems (Fig. 2B and D).
Fig. 3 demonstrates the visual and numeral diﬀerences between the
preclinical Maestro and the clinical Artemis system in an orthotopic
oral cancer model. SBRs of ex vivo tongues were 22.3 ± 2.7 (control
tongue: 1.4) and 4.1 ± 1.2 (control tongue: 1.1) after spraying gGlu-
HMRG for the Maestro and Artemis, respectively.
In brief, both systems could be used to recognize GGT positive
cancer cells of in in vitro and in vivo studies.
Ex vivo evaluation of patient-derived cancer frozen specimen
Fifteen frozen tissue slices with oral cancer were included: 10 with
tongue cancer and 5 with cancer of the ﬂoor of the mouth (Table 1)
(Fig. 4). Fifteen tissue slices without cancer from the same patients were
included. Twelve out of 15 malignant lesions showed ﬂuorescence after
spraying with gGlu-HMRG (sensitivity 80%). Thirteen normal tissue
slices showed either none or only weak ﬂuorescence (speciﬁcity 87%).
Twelve out of 14 ﬂuorescent lesions (86%) were either weak or positive
for GGT. None of the normal tissues stained positive for GGT, while
none of the matching malignant lesions were negative for GGT. In ﬁve
tissue samples some stromal cells showed expression of GGT. However,
no ﬂuorescence was observed in these samples and the epithelial cells
did not show expression of GGT.
Ex vivo evaluation of resection margins after oral cancer surgery
Seven patients undergoing surgery for suspected oral cancer were
included (Table 2). In three patients ﬂuorescence was observed at the
resection margin (Fig. 5). In those patients, routine pathological ex-
amination demonstrated resection margins that were either tumour-
positive or within 1mm of tumour. The margins of the other four pa-
tients were at least 8 mm tumour-free. The epithelial side showed
ﬂuorescence in all except one patient. That patient turned out to have
no malignancy, but parakeratosis, hyperplasia and a chronic lympho-
cytic inﬂammatory inﬁltrate.
Following ﬂuorescence imaging, both the epithelial side and re-
section margin of 16 tissue slices were histopathologically evaluated,
resulting in 32 measurements. A total of 11 slices contained oral cancer
at the epithelial side and all were ﬂuorescent. Three slices with ﬂuor-
escent spots at the epithelial side did not contain tumour. Three patients
had an inadequate resection margin. Two slices with ﬂuorescent spots
contained tumour-positive margins. Four slices were obtained near
ﬂuorescent spots in the resection margins of two patients, but no cancer
cells could be detected. However, routine histopathological examina-
tion in both patients diagnosed a tumour-positive resection margin.
Overall, the sensitivity, speciﬁcity and accuracy of ﬂuorescence ima-
ging were 100% (13/13), 63% (12/19) and 78% (25/32), respectively.
Discussion
This study demonstrates that ﬂuorescence imaging of resection
margins using topically applied activatable tracers can enable detection
of microscopic tumour-positive resection margins. Our results pave the
way for a larger future study, to include more oral cancer patients,
where sensitivity and speciﬁcity may be determined. Additionally, the
factoring in of recurrence-free and disease-free survival would also help
validate this tool, where we could diagnose tumour positive resection
margins during surgery. This would permit for the surgeon to directly
attempt another resection. Moreover, if the utility of the technique is
proven, this could mean a major reduction of costs and time, because
intraoperative frozen section analysis will become unnecessary.
Even though assessing the margins of resected tissue with ﬂuores-
cence imaging could already mean an improvement for surgeons and
patients, it would even be better if also the in vivo resection margin
could be screened with gGlu-HMRG. This requires certain toxicology
studies prior to human use, but topical applications require less ex-
tensive and cheaper studies compared to intravenous administered
tracers. Systemic uptake will probably be very low, which generally
results in favourable safety.
Our work with gGlu-HMRG is not the ﬁrst activatable tracer to be
used clinically for resection. 5-aminolevulinic acid (5-ALA), a non-
ﬂuorescent precursor of haemoglobin, is already being used clinically
[19,20]. Oral administration of 5-ALA induces accumulation of ﬂuor-
escent protoporphyrin IX (emission peak at 635 nm) inside malignant
tumours. A randomized controlled trial demonstrated that 5-ALA and
ﬂuorescence imaging enables a more complete resection and improved
progression-free survival in patients with malignant glioma [21]. Even
though the diseases and the consequences are not comparable, gGlu-
HMRG has the potential to have a similar eﬀect on radical resection
rates and thereby on surgical outcomes.
In this study no GGT-negative oral tumours were encountered in a
total of 21 tumours. Comparably, all ten tumours with oral SCC in-
cluded in the ex vivo study by Shimane et al. were GGT positive and
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showed ﬂuorescence 10min after applying gGlu-HMRG [15]. This is in
concordance with literature; most SCCs demonstrate intense GGT
overexpression [14,22]. However, in the unlikely case of GGT-negative
tumours, applying gGlu-HMRG would result in false-negative results.
This can be detected easily by using the epithelial side of the tumour as
a positive control, as shown in this study.
The ﬂuorescence signals did not align perfectly in all ex vivo frozen
tissues (Fig. 4). There are several explanations. Tissue slices sprayed
with gGlu-HMRG stained afterwards negative for GGT. We therefore
used consecutive, but not identical, slices. Furthermore, gGlu-HMRG is
internalized in vivo after activation. However, this process does not
occur ex vivo in frozen tissue, which may cause activated HMRG to
spread. Lastly, a GGT1 antibody was used, whereas gGlu-HMRG may be
speciﬁc for only certain subtypes of GGT. This hypothesis is reinforced
by the ﬁnding that some stromal cells expressed GGT, but did not show
any ﬂuorescence. Nevertheless, ﬂuorescence signals strongly correlated
with GGT expression.
Seven tissue slices obtained from the proximity of ﬂuorescent spots
did not contain cancer cells. These results were either false-positive, or
caused by sampling errors. Some ﬂuorescent spots were very small (see
Fig. 5), which made it challenging and sometimes impossible to identify
them in a single slice. Unfortunately, the tissue blocks could not com-
pletely used, because suﬃcient tissue needed to be preserved for other
research purposes and additional routine histopathological examina-
tion.
It was sometimes diﬃcult to discriminate between tissue auto-
ﬂuorescence and ﬂuorescence from activated gGlu-HMRG (see Fig. 5).
More research is required to understand the nature of false-positive
ﬂuorescence signals. For example, in this study we chose to subjectively
discriminate between negative, weak and positive ﬂuorescence
(Table 1). The latter two were considered to be positive, hence the
sensitivity of 80% and the speciﬁcity of 87%. However, if only positive
ﬂuorescence would be considered to be positive, the sensitivity would
be 93%, with a speciﬁcity of 53%. One method to reduce non-speciﬁc
(auto)ﬂuorescence is to use diﬀerent ﬂuorophores. For intraoperative
imaging, ﬂuorescence with a wavelength around 800 nm is considered
optimal [23]. That wavelength is capable of deeper tissue penetration
compared to 500 nm [6]. Moreover, tissue autoﬂuorescence is reduced
to a minimum, which will increase sensitivity and speciﬁcity.
Discrimination between zero measurements and activated ﬂuores-
cence signals were currently performed by visual inspection.
Technology exists that compares spectral diﬀerences over time, for
example to detect premalignant cervical lesions after spraying acetic
acid [24]. This method could allow more accurate detection of gGlu-
HMRG activation by tumour-positive resection margins.
Conclusion
In conclusion, this study demonstrates the feasibility of being able to
detect microscopic tumour-positive resection margins using an activa-
table tracer, gGlu-HMRG, in conjunction with a clinical ﬂuorescence
imaging system. Applying this technique would allow intraoperative
screening of the entire resection margin and facilitate direct re-resec-
tion in case of tumour-positivity.
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